HRSA sets January 1, 2027, for the revised 340B rebate pilot

On August 3, 2026, the Health Resources and Services Administration published a revised notice for its 340B Rebate Model Pilot Program.¹

The agency invited eligible drug companies to submit proposals by August 24. The Department of Health and Human Services expects to issue any approvals by September 24, with a January 1, 2027, effective date and a minimum one-year term.¹

This is not merely an application process for drugmakers. Participation is voluntary for companies. Once the department approves an arrangement, covered entities acquiring an included product from that company must use the new method.²

What changes on January 1

The conventional model delivered the statutory price through an upfront discount. Replenishment systems let participating providers identify eligible dispenses, then buy matching replacement inventory at the reduced amount. The revised approach moves that value to a later payment. An organization buys at wholesale acquisition cost, reports the dispense, and waits for the difference between that amount and the ceiling price.³

The notice sets five important operating rules:

• Scope. Eligible products are limited to the 11-digit National Drug Codes for selected drugs in the Medicare Drug Price Negotiation Program for applicability years 2026 and 2027. The rule applies during each product’s price applicability period, regardless of payer or indication.⁴
• Submission. Each approved design must give participating organizations at least 45 calendar days after dispensing to report the required data. It must also allow for extenuating circumstances and later status changes.⁵
• Payment. A company must pay the participating organization or document a denial within 10 calendar days after receiving a complete submission. If information is incomplete, the payment clock restarts when the missing material arrives.⁶
• Denials. A company may not reject payment based on suspected diversion, Medicaid duplicate discounts, eligibility problems, or perceived insufficient full-price purchases. It must direct those concerns to the agency or use the statutory audit process.⁷
• Infrastructure. The company bears the technology-platform cost, must give affected organizations 90 days’ notice, and must provide real-time reconciliation reports, quarterly price files, technical support, and data-security safeguards.⁸

Why the earlier litigation still matters

The 2025 version never began. Hospital associations challenged it under the Administrative Procedure Act, and the United States District Court for the District of Maine entered a nationwide preliminary injunction on December 29, 2025. The First Circuit denied a stay after finding that the government had not shown that it considered hospitals’ reliance interests and major administrative costs. The department later withdrew that design, and the district court vacated and remanded the prior notices and approvals on February 10, 2026.⁹

The revised notice addresses cash flow, staffing, claims data, privacy, denial standards, dispute resolution, and small-entity effects. It also requires payment within 10 days after a complete submission, company-funded technology, and public posting of approved proposals.¹⁰

A separate D.C. Circuit decision defines the agency’s substantive authority. On July 21, 2026, the court held that Section 340B permits a rebate mechanism, but a manufacturer cannot impose one until the Secretary provides for and approves it. The court did not approve this pilot. It resolved a different dispute over unilateral action.¹¹

Together, the decisions make the revised program legally plausible, not litigation-proof.

What organizations should do now

The notice places claims-adjudication functions inside the drug-purchasing process. That increases exposure at the handoffs among pharmacy operations, finance, technology, compliance, and outside vendors.¹²

The agency expects any approvals by September 24.¹ Leadership teams should use that window to:

• Map included products by site, payer, and contract pharmacy.
• Model working-capital needs at the full acquisition price and test the 10-day payment assumption.⁶
• Confirm that systems can report each dispense within 45 days and quickly cure incomplete submissions.⁵
• Assign ownership for reconciliation, denials, disputes, and cash posting.
• Review each vendor’s security, access, retention, and permitted use of claims data.
• Test duplicate-discount and diversion controls without allowing drugmakers to decide issues reserved to the agency.⁷
• Revise agreements if data duties, payment flows, or financial risk shift among a participating organization, its administrator, and its contract pharmacies.

January 1 remains contingent on federal approval and may draw new litigation. It is still a firm planning date. Waiting for final terms would leave organizations about three months to test data, money movement, and accountability across every affected site.¹³

Counsel and executives should treat August 24 as the beginning of implementation, not the end of the public debate.

Read the companion August dates analysis, explore Frost Health Law’s capabilities, or review the applied scholarship that strengthens Chad’s real-world executive and regulatory work. His full background appears on the About page.